Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Apr 10, 2014 1:34pm
181 Views
Post# 22435930

RE:RE:RE:RE:RE:RE:RE:INTERESTING ARTICLE RE LIPID MANAGEMENT , DOSING START

RE:RE:RE:RE:RE:RE:RE:INTERESTING ARTICLE RE LIPID MANAGEMENT , DOSING START Hi G1945V. You are a very active poster and digger. Very helpful. Thanks.

So based on your perspective that rvx-208 would require FDA certification to give credibility to a Zenith sub-IPO then there won't be any Zenith sub-IPOs until about 2017 at best.... 12 month pagse 2c trial, 5 months analysis, 6 months to finds funding for phase 3 trials and then a year or 2 in phase 3.

I'm sure competitors will bury Zenith by then. I can't do anything about my Zenith shares so I guess I'll sit and wait with my fingers crossed. There must be some value in their patents.

On the RVX side I'm assuming that the silence suggests they are working hard at a deal to fund phase 2c. I'm going to hold my RVX position for a month and take stock then.

I'm sensing that inspite of the great scientific and health benefit news I can probably pull back my position in RVX for a year or so and then buy back in as good news begins to develop. PMWP (prove me wrong please) because we all want RVX to kick forward but as we've all seen in other sectors it's not necessarily the best product that wins the day.

Cheers
Toinv :)


Bullboard Posts